CSPHF:OTC-CStone Pharmaceuticals (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.226

Change

0.00 (0.00)%

Market Cap

USD 0.38B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

-3.40 (-0.52%)

USD 36.93B
UCBJY UCB SA ADR

-2.58 (-2.57%)

USD 36.22B
UCBJF UCB SA

-2.89 (-1.45%)

USD 36.22B
GNMSF Genmab A/S

-5.22 (-2.44%)

USD 13.91B
WXIBF WuXi Biologics

N/A

USD 10.26B
WXXWY WuXi Biologics (Cayman) Inc

+0.12 (+2.68%)

USD 9.12B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.24B
ZLDPF Zealand Pharma A/S

-1.13 (-1.09%)

USD 8.01B
IVBIY IVBIY

N/A

USD 7.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.73B

ETFs Containing CSPHF

COPX Global X Copper Miners ET.. 4.58 % 0.65 %

-1.06 (-1.10%)

USD 2.63B
MCSM:CA Manulife Multifactor Cana.. 1.66 % 0.68 %

-0.46 (-1.10%)

CAD 0.29B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.60% 48% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.60% 48% F 32% F
Trailing 12 Months  
Capital Gain -29.60% 48% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.60% 48% F 32% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8,795.44% 97% N/A 99% N/A
Dividend Return 8,795.44% 97% N/A 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A 2% F 1% F
Risk Adjusted Return 8.27% 53% F 40% F
Market Capitalization 0.38B 85% B 67% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.